首页> 外文期刊>Human vaccines & immunotherapeutics. >Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy
【24h】

Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy

机译:在抗逆转录病毒联合治疗时代,HIV感染患者对7价肺炎球菌结合疫苗的初次接种血清反应优于23价肺炎球菌多糖疫苗

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: The objectives of this study were to compare the serologic responses at week 48 to primary vaccination with 23-valent pneumococcal polysaccharide vaccine (PP V) vs. 7-valent pneumococcal conjugate vaccine (PC V); and to identify factors associated with serologic response in HIV-infected adult patients with access to combination antiretroviral therapy (cART). Results: At week 48, patients who received PC V demonstrated a statistically significantly higher response rate to at least 2 serotypes than those who received PP V (37.5% vs. 20.2%, p = 0.006). In multivariate analysis, factors associated with significant antibody responses to at least one or two serotypes included receipt of PC V (adjusted odds ratio [AOR], 2.42 [95% CI, 1.23-4.78] and 3.58 [95% CI. 1.76-7.28], respectively), and undetectable plasma HIV RNA load (< 400 copies/ml) at vaccination (AOR, 1.47 [95% CI, 0.60-3.64] and 3.62 [95% CI, 1.11-11.81], respectively). Methods: One hundred and four CD4-matched pairs of HIV-infected patients who underwent primary pneumococcal vaccination with 23-valent PP V or 7-valent PC V were enrolled for determinations of anti-capsular antibody responses against four serotypes (6B, 14, 19F and 23F) at baseline, 24 weeks and 48 weeks following vaccination. Significant antibody responses were defined as 2-fold or greater increase of antibody levels at week 48 compared with baseline. The logistic regression model was used to determine the factors associated with serologic response to at least one and two serotypes. Conclusions: Primary vaccination with 7-valent PC V achieved a significantly better serologic responses to one or two out of the four serotypes studied at week 48 than with 23-valent PP V in HIV-infected patients in the cART era. Suppression of HIV replication when primary vaccination was administered was associated with better serologic responses.
机译:目的:本研究的目的是比较第23周时23价肺炎球菌多糖疫苗(PP V)与7价肺炎球菌结合疫苗(PC V)的血清学反应;并确定可以接受抗逆转录病毒联合疗法(cART)的HIV感染成人患者的血清学应答相关因素。结果:在第48周,接受PC V的患者对至少2种血清型的应答率在统计学上显着高于接受PP V的患者(37.5%对20.2%,p = 0.006)。在多变量分析中,与至少一种或两种血清型的显着抗体反应相关的因素包括接受PC V(调整后的优势比[AOR],2.42 [95%CI,1.23-4.78]和3.58 [95%CI。1.76-7.28] )和未检测到的血浆HIV RNA载量(<400拷贝/ ml)(分别为AOR,1.47 [95%CI,0.60-3.64]和3.62 [95%CI,1.11-11.81])。方法:招募了104对CD4匹配的HIV感染患者,这些患者接受了23价PP V或7价PC V的原发性肺炎球菌疫苗接种,以确定针对四种血清型的抗荚膜抗体反应(6B,14,疫苗接种后24周和48周在基线(19F和23F)。显着的抗体反应被定义为与基线相比,在第48周时抗体水平增加了2倍或更多。逻辑回归模型用于确定与至少一种和两种血清型的血清学反应相关的因素。结论:在cART时代,在HIV感染患者中,在第48周对7种PCV进行的初次接种对23种PP V的血清学反应明显优于对23种PP V进行研究的4种血清型。进行初次疫苗接种时抑制HIV复制与更好的血清学反应有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号